Discounted Cash Flow (DCF) Analysis Unlevered
BioNano Genomics, Inc. WT EXP 08212... (BNGOW)
$0.05
+0.01 (+19.90%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -15.78 | -26.38 | -37.08 | -73.86 | -120.57 | -124.25 | -166 | -221.80 | -296.34 | -395.94 |
| EBITDA (%) | ||||||||||
| EBIT | -17.10 | -27.51 | -38.56 | -77.22 | -130.41 | -131.21 | -175.30 | -234.22 | -312.94 | -418.11 |
| EBIT (%) | ||||||||||
| Depreciation | 1.32 | 1.13 | 1.48 | 3.37 | 9.84 | 6.96 | 9.30 | 12.42 | 16.60 | 22.18 |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | 16.52 | 17.31 | 38.45 | 250.61 | 113.19 | 190.31 | 254.27 | 339.73 | 453.91 | 606.46 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | 4.51 | 6.33 | 2.78 | 5.32 | 7.50 | 14.07 | 18.79 | 25.11 | 33.55 | 44.83 |
| Account Receivables (%) | ||||||||||
| Inventories | 1.07 | 3.44 | 3.32 | 12.39 | 29.76 | 19.15 | 25.59 | 34.19 | 45.69 | 61.04 |
| Inventories (%) | ||||||||||
| Accounts Payable | 1.35 | 2.70 | 2.93 | 9.70 | 12.53 | 12.73 | 17.01 | 22.73 | 30.37 | 40.57 |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | -0.33 | -0.06 | -0.14 | -0.30 | -0.47 | -0.63 | -0.84 | -1.12 | -1.49 | -1.99 |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.05 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | - |
| Cost of Debt | |
| Tax Rate | -1.44 |
| After-tax Cost of Debt | 2.55% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.608 |
| Total Debt | 11.67 |
| Total Equity | - |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -15.78 | -26.38 | -37.08 | -73.86 | -120.57 | -124.25 | -166 | -221.80 | -296.34 | -395.94 |
| EBIT | -17.10 | -27.51 | -38.56 | -77.22 | -130.41 | -131.21 | -175.30 | -234.22 | -312.94 | -418.11 |
| Tax Rate | -0.08% | -0.07% | -0.07% | 7.32% | -1.44% | 1.13% | 1.13% | 1.13% | 1.13% | 1.13% |
| EBIAT | -17.11 | -27.53 | -38.59 | -71.58 | -132.29 | -129.72 | -173.32 | -231.57 | -309.40 | -413.39 |
| Depreciation | 1.32 | 1.13 | 1.48 | 3.37 | 9.84 | 6.96 | 9.30 | 12.42 | 16.60 | 22.18 |
| Accounts Receivable | - | -1.82 | 3.56 | -2.55 | -2.18 | -6.57 | -4.73 | -6.32 | -8.44 | -11.28 |
| Inventories | - | -2.38 | 0.13 | -9.07 | -17.37 | 10.61 | -6.44 | -8.60 | -11.49 | -15.35 |
| Accounts Payable | - | 1.35 | 0.23 | 6.77 | 2.84 | 0.20 | 4.28 | 5.72 | 7.64 | 10.21 |
| Capital Expenditure | -0.33 | -0.06 | -0.14 | -1.46 | -3.30 | -0.63 | -0.84 | -1.12 | -1.49 | -1.99 |
| UFCF | -16.13 | -29.31 | -33.33 | -73.36 | -139.63 | -119.16 | -171.75 | -229.47 | -306.59 | -409.63 |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | |||||
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -417.82 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | 6.58 |
| Equity Value | - |
| Shares Outstanding | - |
| Equity Value Per Share | - |